XTX301, A Half-Life Extended, Tumor-Selective IL-12, Exerts Potent Anti-Tumor Activity in Mice & has the Potential To Widen the Therapeutic Index of IL-12 Treatment.
Time: 11:30 am
day: Day Two
• mXTX301 potently inhibits tumor growth in a syngeneic mouse model.
• XTX301 is well-tolerated in a repeat dose non-GLP non-human primate study.
• XTX301 may exert potent anti-tumor activity while widening the potential
therapeutic index of IL-12 treatment.